全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2012 

Disease-Toxicant Interactions in Manganese Exposed Huntington Disease Mice: Early Changes in Striatal Neuron Morphology and Dopamine Metabolism

DOI: 10.1371/journal.pone.0031024

Full-Text   Cite this paper   Add to My Lib

Abstract:

YAC128 Huntington's disease (HD) transgenic mice accumulate less manganese (Mn) in the striatum relative to wild-type (WT) littermates. We hypothesized that Mn and mutant Huntingtin (HTT) would exhibit gene-environment interactions at the level of neurochemistry and neuronal morphology. Twelve-week-old WT and YAC128 mice were exposed to MnCl2-4H2O (50 mg/kg) on days 0, 3 and 6. Striatal medium spiny neuron (MSN) morphology, as well as levels of dopamine (DA) and its metabolites (which are known to be sensitive to Mn-exposure), were analyzed at 13 weeks (7 days from initial exposure) and 16 weeks (28 days from initial exposure). No genotype-dependent differences in MSN morphology were apparent at 13 weeks. But at 16 weeks, a genotype effect was observed in YAC128 mice, manifested by an absence of the wild-type age-dependent increase in dendritic length and branching complexity. In addition, genotype-exposure interaction effects were observed for dendritic complexity measures as a function of distance from the soma, where only YAC128 mice were sensitive to Mn exposure. Furthermore, striatal DA levels were unaltered at 13 weeks by genotype or Mn exposure, but at 16 weeks, both Mn exposure and the HD genotype were associated with quantitatively similar reductions in DA and its metabolites. Interestingly, Mn exposure of YAC128 mice did not further decrease DA or its metabolites versus YAC128 vehicle exposed or Mn exposed WT mice. Taken together, these results demonstrate Mn-HD disease-toxicant interactions at the onset of striatal dendritic neuropathology in YAC128 mice. Our results identify the earliest pathological change in striatum of YAC128 mice as being between 13 to 16 weeks. Finally, we show that mutant HTT suppresses some Mn-dependent changes, such as decreased DA levels, while it exacerbates others, such as dendritic pathology.

References

[1]  Huntington's Disease Collaborative Research G (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease chromosomes. Cell 72: 971–083.
[2]  de la Monte SM, Vonsattel JP, Richardson EP Jr (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47: 516–525.
[3]  Graveland G, Williams R, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770–773.
[4]  Vonsattel JP, Myers R, Stevens T, Ferrante R, Bird E, et al. (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559–577.
[5]  Ferrante RJ, Kowall NW, Richardson EP Jr (1991) Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 11: 3877–3887.
[6]  Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, et al. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 101: 3498–3503.
[7]  Andrew SE, Paul Goldberg Y, Kremer B, Telenius H, Theilmann J, et al. (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4: 398–403.
[8]  Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, et al. (1993) Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 2: 1547–1549.
[9]  Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, et al. (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269: 407–410.
[10]  Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60: 1202–1210.
[11]  Hannan AJ (2004) Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease. Acta Biochim Pol 51: 415–430.
[12]  van Dellen A, Hannan AJ (2004) Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 5: 9–17.
[13]  Georgiou N, Bradshaw JL, Chiu E, Tudor A, O'Gorman L, et al. (1999) Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov Disord 14: 320–325.
[14]  Anca MH, Gazit E, Loewenthal R, Ostrovsky O, Frydman M, et al. (2004) Different phenotypic expression in monozygotic twins with Huntington disease. Am J Med Genet A 124A: 89–91.
[15]  Bowman AB, Kwakye GF, Herrero Hernandez E, Aschner M (2011) Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol.
[16]  Gaeta A, Hider RC (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146: 1041–1059.
[17]  Yokel RA (2006) Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 10: 223–253.
[18]  Roth JA, Garrick MD (2003) Iron interactions and other biological reactions mediating the physiological and toxic actions of manganese. Biochem Pharmacol 66: 1–13.
[19]  Aschner M, Erikson KM, Dorman DC (2005) Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol 35: 1–32.
[20]  Erikson KM, John CE, Jones SR, Aschner M (2005) Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter. Environmental Toxicology and Pharmacology 20: 390–394.
[21]  Golub MS, Hogrefe CE, Germann SL, Tran TT, Beard JL, et al. (2005) Neurobehavioral evaluation of rhesus monkey infants fed cow's milk formula, soy formula, or soy formula with added manganese. Neurotoxicol Teratol 27: 615–627.
[22]  Pal PK, Samii A, Calne DB (1999) Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology 20: 227–238.
[23]  Olanow CW (2004) Manganese-Induced Parkinsonism and Parkinson's Disease. Annals of the New York Academy of Sciences 1012: 209–223.
[24]  Milatovic D, Zaja-Milatovic S, Gupta RC, Yu Y, Aschner M (2009) Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl Pharmacol 240: 219–225.
[25]  Autissier N, Rochette L, Dumas P, Beley A, Loireau A, et al. (1982) Dopamine and norepinephrine turnover in various regions of the rat brain after chronic manganese chloride administration. Toxicology 24: 175–182.
[26]  Struve MF, McManus BE, Wong BA, Dorman DC (2007) Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation. Am J Ind Med 50: 772–778.
[27]  Vidal L, Alfonso M, Campos F, Faro LR, Cervantes RC, et al. (2005) Effects of manganese on extracellular levels of dopamine in rat striatum: an analysis in vivo by brain microdialysis. Neurochem Res 30: 1147–1154.
[28]  Gwiazda RH, Lee D, Sheridan J, Smith DR (2002) Low cumulative manganese exposure affects striatal GABA but not dopamine. Neurotoxicology 23: 69–76.
[29]  Reaney SH, Bench G, Smith DR (2006) Brain accumulation and toxicity of Mn(II) and Mn(III) exposures. Toxicol Sci 93: 114–124.
[30]  Gianutsos G, Murray MT (1982) Alterations in brain dopamine and GABA following inorganic or organic manganese administration. Neurotoxicology 3: 75–81.
[31]  Kontur PJ, Fechter LD (1988) Brain regional manganese levels and monoamine metabolism in manganese-treated neonatal rats. Neurotoxicol Teratol 10: 295–303.
[32]  Olanow CW, Good PF, Shinotoh H, Hewitt KA, Vingerhoets F, et al. (1996) Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 46: 492–498.
[33]  Vezer T, Papp A, Hoyk Z, Varga C, Naray M, et al. (2005) Behavioral and neurotoxicological effects of subchronic manganese exposure in rats. Environmental Toxicology and Pharmacology 19: 797–810.
[34]  Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, et al. (2006) Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol 202: 381–390.
[35]  Aschner M (2000) Manganese: brain transport and emerging research needs. Environmental Health Perspectives 103: 429–432.
[36]  Calne DB, Chu NS, Huang CC, Lu CS, Olanow W (1994) Manganism and idiopathic parkinsonism: similarities and differences. Neurology 44: 1583–1586.
[37]  Williams BB, Li D, Wegrzynowicz M, Vadodaria BK, Anderson JG, et al. (2010) Disease-toxicant screen reveals a neuroprotective interaction between Huntington's disease and manganese exposure. J Neurochem 112: 227–237.
[38]  Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555–1567.
[39]  Williams BB, Kwakye GF, Wegrzynowicz M, Li D, Aschner M, et al. (2010) Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system. Toxicol Sci 117: 169–179.
[40]  Kwakye GF, Li D, Bowman AB (2011) Novel high-throughput assay to assess cellular manganese levels in a striatal cell line model of Huntington's disease confirms a deficit in manganese accumulation. Neurotoxicology.
[41]  Dodd CA, Ward DL, Klein BG (2005) Basal Ganglia accumulation and motor assessment following manganese chloride exposure in the C57BL/6 mouse. Int J Toxicol 24: 389–397.
[42]  Kusnoor SV, Parris J, Muly EC, Morgan JI, Deutch AY (2010) Extracerebellar role for Cerebellin1: Modulation of dendritic spine density and synapses in striatal medium spiny neurons. The Journal of Comparative Neurology 518: 2525–2537.
[43]  Garcia BG, Neely MD, Deutch AY (2010) Cortical Regulation of Striatal Medium Spiny Neuron Dendritic Remodeling in Parkinsonism: Modulation of Glutamate Release Reverses Dopamine Depletion-Induced Dendritic Spine Loss. Cereb Cortex 20: bhp317.
[44]  Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87: 387–406.
[45]  Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, et al. (2005) Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease. J Neurosci 25: 4169–4180.
[46]  Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 35: 319–336.
[47]  Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, et al. (2011) Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol Dis 43: 257–265.
[48]  Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, et al. (2004) Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur J Neurosci 19: 2799–2807.
[49]  Guidetti P, Charles V, Chen E-Y, Reddy PH, Kordower JH, et al. (2001) Early Degenerative Changes in Transgenic Mice Expressing Mutant Huntingtin Involve Dendritic Abnormalities but No Impairment of Mitochondrial Energy Production. Experimental Neurology 169: 340–350.
[50]  Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, et al. (2001) Electrophysiological and Morphological Changes in Striatal Spiny Neurons in R6/2 Huntington's Disease Transgenic Mice. J Neurophysiol 86: 2667–2677.
[51]  Nithianantharajah J, Barkus C, Vijiaratnam N, Clement O, Hannan AJ (2009) Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington's disease transgenic mice. Am J Geriatr Psychiatry 17: 196–209.
[52]  Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, et al. (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65: 178–190.
[53]  Qin M, Xia Z, Huang T, Smith CB (2011) Effects of chronic immobilization stress on anxiety-like behavior and basolateral amygdala morphology in Fmr1 knockout mice. Neuroscience 194: 282–290.
[54]  Duan H, Wearne SL, Rocher AB, Macedo A, Morrison JH, et al. (2003) Age-related dendritic and spine changes in corticocortically projecting neurons in macaque monkeys. Cereb Cortex 13: 950–961.
[55]  Grill JD, Riddle DR (2002) Age-related and laminar-specific dendritic changes in the medial frontal cortex of the rat. Brain Res 937: 8–21.
[56]  Bloss EB, Janssen WG, McEwen BS, Morrison JH (2010) Interactive effects of stress and aging on structural plasticity in the prefrontal cortex. J Neurosci 30: 6726–6731.
[57]  Kawaguchi S, Kishikawa M, Sakae M, Nakane Y (1995) Age-related changes in basal dendrite and dendritic spine of hippocampal pyramidal neurons (CA1) among SAMP1TA/Ngs–quantitative analysis by the rapid Golgi method. Mech Ageing Dev 83: 11–20.
[58]  Markham JA, Juraska JM (2002) Aging and sex influence the anatomy of the rat anterior cingulate cortex. Neurobiol Aging 23: 579–588.
[59]  Harmon KM, Wellman CL (2003) Differential effects of cholinergic lesions on dendritic spines in frontal cortex of young adult and aging rats. Brain Res 992: 60–68.
[60]  McNeill TH, Koek LL, Brown SA, Rafols JA (1990) Quantitative analysis of age-related dendritic changes in medium spiny I (MSI) striatal neurons of C57BL/6N mice. Neurobiol Aging 11: 537–550.
[61]  Schmidt-Hieber C, Jonas P, Bischofberger J (2007) Subthreshold dendritic signal processing and coincidence detection in dentate gyrus granule cells. J Neurosci 27: 8430–8441.
[62]  Mainen ZF, Sejnowski TJ (1996) Influence of dendritic structure on firing pattern in model neocortical neurons. Nature 382: 363–366.
[63]  Tsay D, Yuste R (2004) On the electrical function of dendritic spines. Trends Neurosci 27: 77–83.
[64]  Jaslove SW (1992) The integrative properties of spiny distal dendrites. Neuroscience 47: 495–519.
[65]  Woolley CS, Weiland NG, McEwen BS, Schwartzkroin PA (1997) Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 17: 1848–1859.
[66]  Vetter P, Roth A, Hausser M (2001) Propagation of action potentials in dendrites depends on dendritic morphology. J Neurophysiol 85: 926–937.
[67]  Carter AG, Soler-Llavina GJ, Sabatini BL (2007) Timing and location of synaptic inputs determine modes of subthreshold integration in striatal medium spiny neurons. J Neurosci 27: 8967–8977.
[68]  Magee JC (2000) Dendritic integration of excitatory synaptic input. Nat Rev Neurosci 1: 181–190.
[69]  Mel BW (1993) Synaptic integration in an excitable dendritic tree. J Neurophysiol 70: 1086–1101.
[70]  Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA (2011) Impaired dopamine release and uptake in R6/1 Huntington's disease model mice. Neurosci Lett 492: 11–14.
[71]  Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, et al. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 95: 6480–6485.
[72]  Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proceedings of the National Academy of Sciences of the United States of America 97: 6809–6814.
[73]  Johnson MA, Rajan V, Miller CE, Wightman RM (2006) Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. Journal of Neurochemistry 97: 737–746.
[74]  Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA (2010) Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J Neurochem 112: 755–761.
[75]  Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease. J Neurosci 27: 7899–7910.
[76]  Lipe GW, Duhart H, Newport GD, Slikker W Jr, Ali SF (1999) Effect of manganese on the concentration of amino acids in different regions of the rat brain. J Environ Sci Health B 34: 119–132.
[77]  Dydak U, Jiang YM, Long LL, Zhu H, Chen J, et al. (2011) In vivo measurement of brain GABA concentrations by magnetic resonance spectroscopy in smelters occupationally exposed to manganese. Environ Health Perspect 119: 219–224.
[78]  Takeda A, Sotogaku N, Oku N (2002) Manganese influences the levels of neurotransmitters in synapses in rat brain. Neuroscience 114: 669–674.
[79]  Takeda A, Sotogaku N, Oku N (2003) Influence of manganese on the release of neurotransmitters in rat striatum. Brain Res 965: 279–282.
[80]  Burton NC, Schneider JS, Syversen T, Guilarte TR (2009) Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. Toxicol Sci 111: 131–139.
[81]  Guilarte TR, Burton NC, McGlothan JL, Verina T, Zhou Y, et al. (2008) Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem 107: 1236–1247.
[82]  Stanwood GD, Leitch DB, Savchenko V, Wu J, Fitsanakis VA, et al. (2009) Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem 110: 378–389.
[83]  Garcia BG, Neely MD, Deutch AY (2010) Cortical Regulation of Striatal Medium Spiny Neuron Dendritic Remodeling in Parkinsonism: Modulation of Glutamate Release Reverses Dopamine Depletion-Induced Dendritic Spine Loss. Cereb Cortex 20: 2423–2432.
[84]  Day M, Wang Z, Ding J, An X, Ingham CA, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251–259.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133